SG/CALL/NOVO-NORDISK B/1100/0.1/20.12.24 | Market Closed - Boerse Frankfurt Warrants 20:51:15 14/06/2024 BST | ||
| 0.88 EUR | +3.53% |
|
| Current month | +56.14% | ||
| 1 month | +48.33% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 14/06/24 | 0.89 | +4.71% |
| 13/06/24 | 0.85 | -2.30% |
| 12/06/24 | 0.87 | +3.57% |
| 11/06/24 | 0.84 | -7.69% |
| 10/06/24 | 0.91 | +1.11% |
Real-time Boerse Frankfurt Warrants
Last update June 14, 2024 at 08:51 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SU9GMB |
| ISIN | DE000SU9GMB4 |
| Date issued | 16/02/2024 |
| Strike | 1,100 kr |
| Maturity | 20/12/2024 (188 Days) |
| Parity | 10 : 1 |
| Emission price | 0.53 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.98 € |
|---|---|
| Lowest since issue | 0.41 € |
| Spread | 0.03 € |
| Spread % | 3.30% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
991
DKK
Average target price
934.3
DKK
Spread / Average Target
-5.72%
- Stock Market
- Warrants
- Warrant